Acrivon Therapeutics (Acrivon Therapeutics) Net Income : $-64.12 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Acrivon Therapeutics Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Acrivon Therapeutics's Net Income for the three months ended in Mar. 2024 was $-16.49 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-64.12 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Acrivon Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.73.

Acrivon Therapeutics Net Income Historical Data

The historical data trend for Acrivon Therapeutics's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrivon Therapeutics Net Income Chart

Acrivon Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Income

-5.31

-16.24

-31.17

-60.39

Acrivon Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income	Get a 7-Day Free Trial								-12.76	-13.91	-14.47	-19.25	-16.49

Acrivon Therapeutics Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Acrivon Therapeutics's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

	Net Income		(A: Dec. 2023 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-60.388	+	0	+	0	+	0
=	-60.39

Acrivon Therapeutics's Net Income for the quarter that ended in Mar. 2024 is calculated as

	Net Income		(Q: Mar. 2024 )
=	Pre-Tax Income	+	Tax Provision	+	Net Income (Discontinued Operations)	+	Others
=	-16.486	+	0	+	0	+	0
=	-16.49

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-64.12 Mil.

Acrivon Therapeutics (NAS:ACRV) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Acrivon Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

Earnings per Share (Diluted) (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-16.486	-	0)	/	22.591
	=	-0.73

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.

Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.

Acrivon Therapeutics Net Income Related Terms

Thank you for viewing the detailed overview of Acrivon Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrivon Therapeutics (Acrivon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrivon Therapeutics Inc (NAS:ACRV) » Definitions » Net Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472

Website

https://www.acrivon.com

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Executives

Mary Miller	officer: Chief Legal Officer	C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Peter Blume-jensen	director, officer: President and CEO	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Chione Ltd	10 percent owner	SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101, 6015, LARNACA G4 CY
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Rasmus Holm-jorgensen	officer: Chief Financial Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Eric Devroe	officer: Chief Operating Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Anastasis Nikolaou	10 percent owner	C/O CHIONE LTD/ SIMOU MENARDOU 5, KIFISIA COURT,OFFICE 225, LARNACA G4 6015
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Erick Gamelin	officer: Chief Medical Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Kristina Masson	director, officer: EVP - Business Operations	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116